Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - ALMB-0166 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF PARKINSON'S DISEASE

VOLUNTARY ANNOUNCEMENT - ALMB-0166 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF PARKINSON'S DISEASE

June 23, 2025

a250915_01.png

a250915_02.png

Previous: HIGH-CONCENTRATION HYDROXOCOBALAMIN HYDROCHLORIDE INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA (MMA)

Next: VOLUNTARY ANNOUNCEMENT - ENTERING INTO STRATEGIC RESEARCH COLLABORATION AGREEMENT WITH ASTRAZENECA

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat